Inclusion Criteria:  Male or female patients 18 years of age or older; Newly diagnosed MM patients who fulfill the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (Revised in 2020) Standards; Patients with relapsed MM who have received 1 to 3 prior therapies (including lenalidomide); There must be a washout period of two weeks (14 days) from the last treatment (excluding dexamethasone treatment); Previously untreated subjects with ixazomib or pomalidomide; Subjects of childbearing age should take effective contraceptive measures and must agree to comply with all contraceptive requirements; Contraceptive requirements: women with fertility must decide to adopt two reliable contraceptive methods at the same time (a highly effective method of contraception-fallopian tube ligation, intrauterine contraceptive device, hormones (contraceptive pills, needles, patches, vaginal rings or implants) ) Or partner's vas deferens ligation, another effective contraceptive program-male rubber or synthetic condoms, diaphragm or cervical cap); unless the cause of hysterectomy, or a history of infertility in time, effective contraception is also required. Men must agree to use a latex condom during sexual contact with a Females of childbearing potential even if they have had a successful vasectomy; Patients must have measurable disease defined by at least 1 of the following 3 measurements: Serum M-protein≥5 g/ L, Urine M-protein≥200 mg/24 hours, Serum free light chain assay: involved free light chain level≥100 mg/L, provided that the serum free light chain ratio is abnormal; Hematology satisfies the following conditions: when myeloma cells are less than 50%, ANC≥1.0×109/L (including with the support of G-CSF) and PLT≥75×109/L; when myeloma cells are ≥50% , Any ANC and PLT≥50×109/L; Must be able to take antithrombotic drugs, such as low molecular weight heparin sodium or aspirin; Physical performance status (ECOG) score ≤ 2; Expected lifetime More than 3 months. Patients participate in the study based on his/her own will and voluntarily sign the informed consent form.  Exclusion Criteria:  Patients who are allergic or intolerant to ixazomib, pomalidomide or dexamethasone; Patients who have used ixazomib or pomalidomide; Patients who are resistant to bortezomib; Patients with severe cardiopulmonary insufficiency; Patients with severe liver and kidney dysfunction, ALT or AST or bilirubin exceeds 3 times the upper limit of normal range, and the creatinine clearance rate is less than 30 ml/min; patients with other malignancies (except for carcinoma in situ); patients with serious bacterial or viral infections, such as HIV or HBV, HCV, etc.; Patients with active new thrombosis or unwilling to receive anti-thrombotic therapy; Patients with extramedullary disease; Patients with peripheral neuropathy ≥ Grade 3; Pregnant or lactating women; Can't strictly contraception; Psychiatric patients and patients with other serious mental illness that potentially impact signing informed consent and disease consultation and follow-up; Patients who have participated in other clinical trials within one month.